已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Napabucasin versus placebo in refractory advanced colorectal cancer: a randomised phase 3 trial

医学 危险系数 安慰剂 内科学 结直肠癌 临床终点 临床试验 癌症 肿瘤科 外科 置信区间 病理 替代医学
作者
Derek J. Jonker,Abhishek Joshi,Takayuki Yoshino,Sharlene Gill,Jeremy Shapiro,Atsushi Ohtsu,John Zalcberg,Michael M. Vickers,Alice C. Wei,Yuan Gao,Niall C. Tebbutt,Ben Markman,Timothy Price,Taito Esaki,Sheryl Koski,Matthew Hitron,Wěi Li,Youzhi Li,Nadine M Magoski,Chiang J. Li,John Simes,Dongsheng Tu,Christopher J. O’Callaghan
出处
期刊:The Lancet Gastroenterology & Hepatology [Elsevier]
卷期号:3 (4): 263-270 被引量:135
标识
DOI:10.1016/s2468-1253(18)30009-8
摘要

Napabucasin is a first-in-class cancer stemness inhibitor that targets STAT3, which is a poor prognostic factor in colorectal cancer. This study aimed to test napabucasin in advanced colorectal cancer.This study was a double-blind randomised phase 3 trial done at 68 centres in Canada, Australia, New Zealand, and Japan. Patients with advanced colorectal cancer with a good Eastern Cooperative Oncology Group (ECOG) performance status (0-1) for whom all available standard therapies had failed were eligible for the study. Patients were randomly assigned (1:1) to receive placebo or napabucasin through a web-based system with a permuted block method, after stratification by ECOG performance status, KRAS status, previous VEGF inhibitor treatment, and time from diagnosis of metastatic disease. Napabucasin 480 mg or matching placebo was taken orally every 12 h. All patients received best supportive care. The primary endpoint was overall survival assessed in an intention-to-treat analysis. This is the final analysis of this trial, which is registered at ClinicalTrials.gov, number NCT01830621.Accrual began on April 15, 2013, and was stopped for futility on May 23, 2014, at which point 282 patients had undergone randomisation (138 assigned to the napabucasin group and 144 to the placebo group). Overall survival did not differ significantly between groups: median overall survival was 4·4 months (95% CI 3·7-4·9) in the napabucasin group and 4·8 months (4·0-5·3) in the placebo group (adjusted hazard ratio [HR] 1·13, 95% CI 0·88-1·46, p=0·34). The safety population included 136 patients in the napabucasin group and 144 patients in the placebo group. More patients who received napabucasin had any grade of treatment-related diarrhoea (108 [79%] of 136 patients), nausea (69 [51%]), and anorexia (52 [38%]) than did patients who received placebo (28 [19%] of 144 patients, 35 [24%], and 23 [16%], respectively). The most common severe (grade 3 or worse) treatment-related adverse events were abdominal pain (five [4%] patients receiving napabucasin vs five [3%] receiving placebo), diarrhoea (21 [15%] vs one [1%]), fatigue (14 [10%] vs eight [6%]), and dehydration (six [4%] vs one [1%]). 251 (89%) patients had data on pSTAT3 expression, of whom 55 (22%) had pSTAT3-positive tumours (29 in the napabucasin group, 26 in the placebo group). In a prespecified biomarker analysis of pSTAT3-positive patients, overall survival was longer in the napabucasin group than in the placebo group (median 5·1 months [95% CI 4·0-7·5] vs 3·0 months [1·7-4·1]; HR 0·41, 0·23-0·73, p=0·0025).Although there was no difference in overall survival between groups in the overall unselected population, STAT3 might be an important target for the treatment of colorectal cancer with elevated pSTAT3 expression. Nevertheless, these results require validation.Canadian Cancer Society Research Institute and Boston Biomedical.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
今我来思完成签到 ,获得积分10
刚刚
小孩完成签到 ,获得积分10
2秒前
wing发布了新的文献求助30
3秒前
Robin发布了新的文献求助10
3秒前
Crystal完成签到 ,获得积分10
4秒前
David发布了新的文献求助200
8秒前
雨蝶完成签到,获得积分10
8秒前
慕青应助CR7采纳,获得10
12秒前
在水一方应助yulee采纳,获得10
12秒前
Robin完成签到,获得积分20
13秒前
14秒前
HMBB完成签到,获得积分10
15秒前
999完成签到,获得积分10
16秒前
慌慌张张的张张完成签到 ,获得积分10
17秒前
学者风范完成签到 ,获得积分10
17秒前
不懈奋进应助夏筱采纳,获得30
17秒前
季夏完成签到,获得积分10
17秒前
hunee完成签到,获得积分10
17秒前
默默完成签到 ,获得积分10
18秒前
大模型应助普外科老白采纳,获得10
19秒前
20秒前
sghpv发布了新的文献求助10
21秒前
一一一多完成签到 ,获得积分10
22秒前
zayne完成签到 ,获得积分10
23秒前
九千岁完成签到,获得积分10
23秒前
TangWuyue完成签到,获得积分10
24秒前
25秒前
独指蜗牛完成签到 ,获得积分10
26秒前
yulee发布了新的文献求助10
26秒前
26秒前
tt完成签到 ,获得积分10
27秒前
yhnsag完成签到,获得积分10
28秒前
普外科老白完成签到,获得积分10
28秒前
Jalynn2044完成签到 ,获得积分10
29秒前
若水完成签到,获得积分10
29秒前
29秒前
tejing1158完成签到 ,获得积分10
31秒前
苏卿应助夏筱采纳,获得10
31秒前
wanli完成签到,获得积分10
31秒前
31秒前
高分求助中
Continuum Thermodynamics and Material Modelling 3000
Production Logging: Theoretical and Interpretive Elements 2700
Mechanistic Modeling of Gas-Liquid Two-Phase Flow in Pipes 2500
Structural Load Modelling and Combination for Performance and Safety Evaluation 1000
Conference Record, IAS Annual Meeting 1977 610
電気学会論文誌D(産業応用部門誌), 141 巻, 11 号 510
Virulence Mechanisms of Plant-Pathogenic Bacteria 500
热门求助领域 (近24小时)
化学 材料科学 生物 医学 工程类 有机化学 生物化学 物理 纳米技术 计算机科学 内科学 化学工程 复合材料 基因 遗传学 物理化学 催化作用 量子力学 光电子学 冶金
热门帖子
关注 科研通微信公众号,转发送积分 3561720
求助须知:如何正确求助?哪些是违规求助? 3135436
关于积分的说明 9412175
捐赠科研通 2835827
什么是DOI,文献DOI怎么找? 1558687
邀请新用户注册赠送积分活动 728434
科研通“疑难数据库(出版商)”最低求助积分说明 716832